{
  "id": "56c313d150c68dd416000002",
  "type": "yesno",
  "question": "Does nifedipine inhibit L-type calcium channels?",
  "ideal_answer": "Yes, nifedipine is a typical blocker of L-type calcium channels.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16573711",
    "http://www.ncbi.nlm.nih.gov/pubmed/10320722",
    "http://www.ncbi.nlm.nih.gov/pubmed/10404034",
    "http://www.ncbi.nlm.nih.gov/pubmed/24752219",
    "http://www.ncbi.nlm.nih.gov/pubmed/24513517",
    "http://www.ncbi.nlm.nih.gov/pubmed/9388008",
    "http://www.ncbi.nlm.nih.gov/pubmed/17346891",
    "http://www.ncbi.nlm.nih.gov/pubmed/10900233",
    "http://www.ncbi.nlm.nih.gov/pubmed/9126675",
    "http://www.ncbi.nlm.nih.gov/pubmed/9399968",
    "http://www.ncbi.nlm.nih.gov/pubmed/12753410",
    "http://www.ncbi.nlm.nih.gov/pubmed/24680380",
    "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
    "http://www.ncbi.nlm.nih.gov/pubmed/11273667",
    "http://www.ncbi.nlm.nih.gov/pubmed/18326812",
    "http://www.ncbi.nlm.nih.gov/pubmed/8647712",
    "http://www.ncbi.nlm.nih.gov/pubmed/16650887",
    "http://www.ncbi.nlm.nih.gov/pubmed/12205133",
    "http://www.ncbi.nlm.nih.gov/pubmed/8793089",
    "http://www.ncbi.nlm.nih.gov/pubmed/15550786",
    "http://www.ncbi.nlm.nih.gov/pubmed/9259470",
    "http://www.ncbi.nlm.nih.gov/pubmed/9882694",
    "http://www.ncbi.nlm.nih.gov/pubmed/23690182",
    "http://www.ncbi.nlm.nih.gov/pubmed/23200725",
    "http://www.ncbi.nlm.nih.gov/pubmed/25340466",
    "http://www.ncbi.nlm.nih.gov/pubmed/10805657",
    "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
    "http://www.ncbi.nlm.nih.gov/pubmed/11726244",
    "http://www.ncbi.nlm.nih.gov/pubmed/10564356",
    "http://www.ncbi.nlm.nih.gov/pubmed/15335104",
    "http://www.ncbi.nlm.nih.gov/pubmed/15350645",
    "http://www.ncbi.nlm.nih.gov/pubmed/20432454",
    "http://www.ncbi.nlm.nih.gov/pubmed/19634509"
  ],
  "snippets": [
    {
      "text": "Nifedipine, an L-type calcium channel blocker, reduced the expression of synaptogamin and syntaxin and blocked the suppressive effect of vecuronium, suggesting that both agents inhibit presynaptic L-type calcium channels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200725",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with nifedipine to inhibit calcium influx via the L-type channel Cav1.2 (alpha(1C)) inhibited the TGFbeta stimulated increase in ANK expression at all phases of chondrogenesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20432454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, we found that PKCepsilon-induced stellation was significantly reduced by the specific L-type channel blocker nifedipine, indicating that calcium influx through VGCC mediates the change in astrocyte morphology induced by PKCepsilon.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, APV and nifedipine, an inhibitor of L-type calcium channels, failed to inhibit LTP when administered following the slow increase in ethanol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17346891",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both the metallic ions Cd2+ and Ni2+, known to inhibit voltage-gated calcium channels and T-type channels, respectively, and verapamil and nifedipine, typical blocker of L-type calcium channels completely prevented the hypoxic neuronal NO generation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15350645",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Further, the L-type calcium channel blocker, nifedipine, was able to inhibit the initial increase in [Ca2+]i, suggesting that at least this phase of the TMT effect was mediated by calcium channels, although nifedipine had no significant effect on the time to reach the maximal [Ca2+]i level",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8647712",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with omega-conotoxin GVIA (3 microM) or nifedipine (10 microM) to inhibit Ca(2+) influx through N- or L-type voltage-dependent calcium channels (VDCCs), respectively, also decreased the rate of AP repolarization and increased AP duration",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12205133",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Concentrations of nifedipine (10 microM) and nimodipine (3 microM) that maximally inhibit L-type calcium channels reduced the sI(AHP) by 30 and 50%, respectively",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10805657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Consequently, it was demonstrated in the present study that nimodipine and nitrendipine inhibit both L- and N-type calcium channels and thus seem to be unique among the dihydropyridines examined in their effects on calcium channels in dibutyryl cAMP-differentiated neuroblastoma x glioma hybrid NG 108-15 cells, whereas nifedipine and niguldipine appear to block mainly L-type calcium channels",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9259470",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, APV and nifedipine, an inhibitor of L-type calcium channels, failed to inhibit LTP when administered following the slow increase in ethanol",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17346891",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Calcium-channel antagonists, omega-conotoxin GVIA (omega-CgTx GVIA; N-type), nifedipine (L-type), and omega-conotoxin MVIIC (omega-CmTx MVIIC; P/Q type), were used to characterize the voltage-operated Ca(2+) channels (VOCCs) involved in this release",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11104511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18326812",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "L-type calcium channel antagonist nifedipine reduces neurofilament restitution following traumatic optic nerve injury.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15335104",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Nifedipine, an L-type calcium channel blocker, restores the hypnotic response in rats made tolerant to the alpha-2 adrenergic agonist dexmedetomidine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399968",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Comparison of L-type calcium channel blockade by nifedipine and/or cadmium in guinea pig ventricular myocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10900233",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Nifedipine inhibits picrotoxin-induced seizure activity: further evidence on the involvement of L-type calcium channel blockers in epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16573711",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4273755",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009543",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020746"
  ],
  "exact_answer": "Yes"
}